Source chain
SEC filings, XBRL financials, federal awards, insider trades, patents, market data, and location-linked context are fused into one company graph.
Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Ticker RDGL · OTC · DE
Source: SEC EDGAR, XBRL financials, federal awards, insider trades, patents, and the Sprytne company graph. Updated 2025-03-24. This page is refreshed with live page data and deterministic offline enrichments.
VIVOS INC is a U.S. business entity operating within the Surgical & Medical Instruments & Apparatus sector (SIC 3841). Publicly traded on the OTC under the ticker symbol RDGL, the company is incorporated in Delaware. Based on SEC EDGAR filings, RDGL reported fiscal year 2024 revenue of $28K, reflecting a year-over-year growth of 43.6%. Our proprietary Semantic Risk Score of 18 indicates high transparency and low reporting risk, derived from the frequency and consistency of 10-K, 10-Q, and 8-K filing patterns. As part of the SIC 3841 classification, VIVOS INC serves as a key benchmark for investors and analysts monitoring Delaware corporate performance.
Why this page is strong for search, retrieval, and mobile reading.
Source chain
SEC filings, XBRL financials, federal awards, insider trades, patents, market data, and location-linked context are fused into one company graph.
Freshness
The page surface always includes the latest 10-K and 10-Q signals, plus freshness widgets for the most recent filing dates.
Retrieval quality
The page is structured for citations, peer comparison, and mobile scanning instead of burying the answer in long-form text alone.
Compact provenance trail for fast scanning, citations, and model retrieval.
Primary records
SEC EDGAR, XBRL filings, and Secretary of State records form the canonical identity layer.
Enrichment layer
Federal awards, patents, insider trades, stock price, and logistics enrich the company graph without inventing fields.
Cross-links
Related companies, industry pages, city, ZIP, street, and money-place context keep the page connected and retrievable.
Comparison based on Standard Industrial Classification (SIC) mapping from SEC EDGAR filings.
Surgical & Medical Instruments & Apparatus
Industry mapping: Surgical & Medical Instruments & Apparatus
Filing data sourced from SEC EDGAR signals. 10-K = annual report · 10-Q = quarterly · 8-K = material event.
Numbers parsed from us-gaap XBRL tags in the company's most recent annual report.View source on SEC EDGAR →
⚠ Data quality note: Some metrics were filtered due to high volatility in XBRL tags. Only verified figures are shown below.
VIVOS INC (RDGL)— Key efficiency & solvency metrics · FY2024
Debt-to-Equity
Sector avg: 2.45
Current Ratio
Sector avg: 3.95
| Key Metric | Company | Industry Avg | Status |
|---|---|---|---|
| Total RevenueYoY: +43.6% | $28K | $1.38B | ▼ Lagging |
| Net IncomeYoY: -0.5% | $-2,910,448 | — | — |
| Debt-to-EquityTotal liabilities / stockholders equity. Lower = safer. | 0.04 | 2.45 | ▲ Stable |
| Current RatioCurrent assets / current liabilities. Above 1.0 = solvent. | 25.91 | 3.95 | ▲ Outperform |
Source: SEC EDGAR XBRL filings (10-K annual reports). Industry benchmarks derived from 116 companies in SIC 3841.
Disclaimer: All financial data is sourced from raw SEC EDGAR filings. Sprytne.com provides automated data visualization and algorithmic analysis for informational purposes only. This is NOT financial advice, a recommendation to buy/sell, or a guarantee of accuracy. Always verify data via official SEC sources before making investment decisions.
Federal Contracts
STUDY OF E-CIGARETTE AEROSOL TOXICITY IN IN VIVO NONCLINICAL MODELS.
PRECLINICAL IN VITRO AND IN VIVO SCREENING ASSAYS FOR CANCER PREVENTIVE AGENT DEVELOPMENT
PRECLINICAL IN VITRO AND IN VIVO SCREENING ASSAYS FOR CANCER PREVENTIVE AGENT DEVELOPMENT
THE PRINCIPAL OBJECTIVES OF THIS ACQUISITION ARE THE WEB-BASED ACQUISITION OF NEW COMPOUNDS FOR TESTING AND THE RECEIPT, STORAGE, INVENTORY, DISTRIBUTION, DOCUMENTATION, AND CONTROL OF ALL SYNTHETIC COMPOUNDS, PURIFIED NATURAL PRODUCTS, AND BULK DRUGS. ALL NEW POTENTIAL CHEMOTHERAPEUTIC AGENTS EVALUATED BY THE PROGRAM, WHETHER SINGLE COMPOUNDS OR PLATED MATERIALS, ARE RECEIVED, REGISTERED IN THE PROGRAM, AND DISTRIBUTED BY THIS CONTRACT. THIS CONTRACT IS ALSO RESPONSIBLE FOR THE MANAGEMENT OF CORRESPONDENCE TO AND FROM THE COMPOUND SUPPLIERS; FOR CREATION, USING THE WEB-BASED ACQUISITION PROCEDURES, AND MAINTENANCE OF THE CHEMICAL DATABASE; SYSTEMATIC FILE AND RECORD KEEPING; AND REACQUISITION OF NEEDED SAMPLES FOR CONTINUED CHEMICAL STUDIES, IN VITRO TESTING AND SUBSEQUENT IN VIVO STUDIES.
IN VITRO AND IN VIVO CHARACTERIZATION OF FILOVIRUS.
OTHER FUNCTIONS PRECLINICAL IN VITRO AND IN VIVO SCREENING FOR CANCER PREVENTIVE AGENTS DEVELOPMENT
PRECLINICAL IN VITRO AND IN VIVO SCREENING ASSAYS FOR CANCER PREVENTIVE AGENT DEVELOPMENT
THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION.
THE WORK WILL SUPPORT THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY'S (DARPA) IN VIVO NANOPLATFORMS PROGRAM (IVN). IVN SEEKS TO DEVELOP NEW CLASSES OF ADAPTABLE NANOPARTICLES FOR PERSISTENT, DISTRIBUTED, UNOBTRUSIVE PHYSIOLOGIC AND ENVIRONMENTAL SENSING AS WELL AS THE TREATMENT OF PHYSIOLOGIC ABNORMALITIES, ILLNESS AND INFECTIOUS DISEASE.
THE CONTRACTOR SHALL PERFORM THE SERVICES IN ACCORDANCE WITH THE STATEMENT OF WORK, "CABIG IN VIVO IMAGING WORKSPACE."
Source: USAspending.gov (Official Federal Award Data). Reflects prime contracts only. Last sync: 2026-03-30.
Compared to 151 peers in Surgical & Medical Instruments & Apparatus (SIC 3841)
Revenue
Net Margin
SEC EDGAR XBRL filings by fiscal year
Side-by-side financial showdown — revenue, margins, and growth.
Based on NAICS.
Methodology & compliance note
Data is aggregated from SEC EDGAR and Secretary of Statepublic records. Any analytics such as "market share" are statistical estimates (proxy models) and are not official audits, valuations, or investment advice. Sprytne.com is an independent data aggregator and is not connected with any government agency.Learn more →